Israel’s Pulsenmore Secures New Contract With Clalit Health Services For IVF Use

Israeli home ultrasound developer Pulsenmore announced on Monday it has secured a multimillion-dollar contract to supply its portable device for self-examination of follicles in IVF (in vitro fertilization) and fertility preservation processes to Clalit Health Services, Israel’s largest healthcare organization.

As part of the agreement, Clalit Health Services is expected to purchase thousands of units with a minimum annual order over the course of four years, at a total of approximately $11 million.

Founded in 2015, Pulsenmore has developed a handheld tele-ultrasound device that allows expecting parents to perform at-home scans. This device limits the need for hospital visits and reduces unnecessary emergency room visits, which is particularly beneficial during the ongoing pandemic.

Pulsenmore already has an agreement with Clalit Health Services to provide its pregnant members with the company’s product. The earlier contract is to provide the organization with its flagship home device for fetal ultrasound, Pulsenmore ES, including an initial order of $6 million. The device was immediately rolled out to Clalit patients and almost 15,000 Pulsenmore home ultrasound scans have been performed by pregnant women and reviewed by Clalit’s healthcare professionals to date.

The standard IVF procedure requires numerous ultrasound scans – sometimes daily – for the assessment of follicle size and endometrial thickness, which are critical parameters in determining optimal timing for retrieving eggs for fertilization. The new follicular tracking ultrasound device, Pulsenmore FC, will enable Clalit’s fertility patients to perform ultrasound scans at home, which are then viewed and assessed remotely by her healthcare professional.

At the outset of the COVID-19 pandemic, IVF clinics in Israel and worldwide were forced to shut down, leaving patients stranded at critical moments of treatment cycles potentially missing precious opportunities for egg retrieval and fertilization. Such occurrences could be prevented in the future with the Pulsenmore FC solution.

Our unique expertise in ultrasound technology is playing a key role in the global home care revolution. We are working at full speed to execute our business strategy, expand sales, and complete a series of clinical trials for additional ultrasound applications that are being developed at Pulsenmore,” Dr. Elazar Sonnenschein, CEO of Pulsenmore said, “Our solutions are major pillars in the global trend adopting more extensive remote healthcare capabilities and transforming them into the new standard of care.”